Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

• While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival. 
• Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma.
• The company said it now intends to engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie.

Genmab A/S (GMAB) said on Friday that its late-stage trial evaluating drug Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.

While the study also showed an improvement in other key aspects such as complete response rates and duration of response, it did not demonstrate a statistically significant improvement in overall survival, the company said. While progression-free survival represents the time a patient lives with cancer without it getting worse or dying, overall survival is the length of time from diagnosis or treatment start until death from any cause.

Study Details

Genmab enrolled 483 patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma in the trial who had undergone at least one prior line of therapy. These patients were ineligible for high-dose chemotherapy, the company said.

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common and aggressive type of non-Hodgkin lymphoma, a blood cancer involving rapid growth of large B-lymphocytes in the lymphatic system, lymph nodes, and other organs, often presenting as fast-growing masses or swollen nodes with symptoms like fever, night sweats, and weight loss. According to Genmab, there are approximately 25,000 new cases of DLBCL diagnosed each year in the U.S.

The company said it intends to now engage with regulatory authorities to discuss the next steps for the drug together with its partner AbbVie. Epcoritamab, being co-developed by Genmab and AbbVie, is already approved in several countries for the treatment of certain lymphomas.

Shares of GMAB fell 5% at the time of writing.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around GMAB stock stayed within the ‘bearish’ territory coupled with ‘high’ message volume.

Meanwhile, sentiment around ABBV shares rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.

A Stocktwits user sees GMAB stock plummet down to $20 from current levels.

GMAB stock has gained 51% over the past 12 months while ABBV shares added 24%. 

Read More: NVO Shares Rise On Strong Kickstart For Wegovy Pill In US: Retail Eyes Up To $110 As ‘Fair Value’

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on